Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc., a biopharmaceutical company that develops transformative therapies for disease areas of significant unmet needs, in a transaction valued at approximately $1.9 billion. The acquisition supports Sanofi’s strategy to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio. Rezurock is a recently FDA-approved, first-in-class treatment for chronic graft-versus-h...